Advance of immune checkpoint inhibitors and clinical trials in glioma

Abstract

Glioma is the most common primary intracranial malignant tumor, and glioblastoma has the worst prognosis. In recent years, immunotherapy targeting immune checkpoints has shown promising results in various solid tumors, and has also become a potential breakthrough in the field of glioma treatment, which has attracted the attention of worldwide neurosurgeons and neuro ⁃ oncologists. This paper reviews the literature about immune checkpoint molecules and the clinical trials of immune checkpoint inhibitors, and briefly introduces the research status of immunotherapy in glioma. We hope to provide some references for the design and development of subsequent clinical studies of glioma immunotherapy in China.DOI：10.3969/j.issn.1672⁃6731.2020.02.005